Together, our findings indicate that CDK6 and LRP1B have significant potential as indicators of prognosis and lymph node metastasis in patients with EJA and could be targeted for molecular targeted therapy. Here, CDK6 is linked to metastatic malignant neoplasm in the lymph nodes.